J&J Expands Immunology Portfolio with Infliximab and Golimumab

Johnson & Johnson (J&J) has taken on responsibility for the sales and marketing of infliximab and golimumab in the UK. These two anti-inflammatory medicines will be added to J&J's immunology portfolio, expanding its offerings in this area.

Infliximab is used to treat a range of conditions including rheumatoid arthritis, Crohn's disease, and psoriasis, while golimumab treats RA, polyarticular juvenile idiopathic arthritis, and ulcerative colitis. The two medicines were previously commercialized by Merck Sharp & Dohme (UK) Limited (MSD), which transferred their distribution to Janssen-Cilag Ltd, a Johnson & Johnson Company.

J&J emphasized that the transition process was collaborative with MSD to ensure minimal disruption to patients using these medications. The company views this addition as a significant milestone in its commitment to providing reliable healthcare solutions for those in need.